Phase 1CompletedAge-related condition
A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers
A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge
- Sponsor
- Theranexus (Industry)
- Enrolment
- 152 enrolled
- Conditions
- Cognitive Impairment; Alzheimer Disease
- Interventions
- THN 201; Donepezil; Placebo
- Ages
- adults
- Registry
- NCT03698695
Full record on ClinicalTrials.gov
From the registry
This study explores the safety, pharmacodynamics and pharmacokinetics of THN201 a combination of donepezil and mefloquine to improve cognitive function in healthy male volunteers after impairment by a scopolamine challenge.
Primary outcomes
- Pharmacodynamics: Cognitive function measured with the Cognitive Drug Research (CDR) test battery
History
Last registry update
Study completion
Primary completion
Registered
Started